Focused On-demand Library for Receptor-type tyrosine-protein phosphatase O

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We employ our advanced, specialised process to create targeted libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q16827

UPID:

PTPRO_HUMAN

Alternative names:

Glomerular epithelial protein 1; Protein tyrosine phosphatase U2

Alternative UPACC:

Q16827; A0AV39; Q13101; Q8IYG3; Q9UBF0; Q9UBT5

Background:

Receptor-type tyrosine-protein phosphatase O, also known as Glomerular epithelial protein 1 and Protein tyrosine phosphatase U2, plays a crucial role in kidney function. It exhibits tyrosine phosphatase activity, influencing podocyte structure and function, thereby regulating the glomerular pressure/filtration rate relationship.

Therapeutic significance:

Linked to Nephrotic syndrome 6, a severe renal disorder marked by proteinuria and potential progression to end-stage renal failure, this protein's gene variants are pivotal in disease manifestation. Understanding its role could lead to novel therapeutic strategies for managing steroid-resistant forms of the syndrome.